

## Relation between Voice Handicap Index (VHI) and disease severity in Iranian patients with Parkinson's disease

Fatemeh Majdinasab<sup>1</sup>, Siamak Karkheiran<sup>2</sup>, Negin Moradi<sup>3</sup>, Gholam Ali Shahidi<sup>4</sup>  
Masoud Salehi<sup>5</sup>

Department of Speech Therapy, School of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran.

Received: 19 May 2012

Revised: 8 August 2012

Accepted: 8 September 2012

### Abstract

**Background:** One third of patients with Parkinson's disease (PD) have mentioned "dysphonia" as their most debilitating communication deficit. Patient-based measurements, such as Voice Handicap Index (VHI) add necessary supplementary information to clinical and physiological assessment. There are a few studies about relation between VHI and disease severity in PD, although none of them showed any significant correlation. The goal of this study was to find correlation between these variables in Iranian PD patients.

**Method:** This cross-sectional, analytical and non-interventional study was done on 23 PD patients who reported a voice disorder related to their disease. They were selected from attendants of movement disorders clinic of Hazrat Rasool Akram Hospital. The relationship between disease severity (according to Hoehn and Yahr/H&Y and Unified Parkinson's Disease Rating Scale-part3 /UPDRS-III) and VHI questionnaire (and its 3 domains) was investigated based on patients' sex, UPDRS-III score H&Y and VHI.

**Results:** Total VHI and its 3 domains had no relationship with disease severity (H&Y) in all patients and by sex separation. However, there was a positive correlation between VHI and disease severity (UPDRS-III) ( $r=0.485$ ). There was also a relation between physical and functional domains of VHI and UPDRS ( $r_p=0.530$ ,  $r_f=0.479$ ) while no relationship observed regarding sex differences. 9 out of 18 UPDRS-III items had strong relationship with VHI (total and 3 subscales).

**Conclusion:** Iranian PD patients feel handicap according to voice disorder caused by PD. Patient satisfaction of voice decreases with the disease severity and progression. A larger sample size is necessary to find relationship in genders. VHI is an important issue could be offered to be used in PD beside other assessments

**Keywords:** Parkinson's disease, Disease severity, Voice, VHI, Quality of life.

### Introduction

Parkinson's disease (PD) is the second common neurodegenerative disease in the world, after Alzheimer's disease (1). It is

caused by gradual death of many neuronal systems specially dopaminergic neurons in substantia nigra pars compacta (2-4). The most important risk factor of PD is "age" (5, 6). By increasing of age, the prevalence of

1. (Correspondence author), MSc of speech and language pathology, Department of Speech Therapy, Jundishapur University of Medical Sciences, Ahvaz, Iran. madjdinassab@yahoo.com

2. Neurologist, Movement Disorders Clinic, Rasool Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran. Siamak.karkheiran@gmail.com

3. PhD of speech and language pathology, Lecturer of Speech & language pathology department, Jundishapur University of Medical Sciences, Ahvaz, Iran. neginmoradist@gmail.com

4. Assistant Professor of Neurology, Tehran University of Medical Sciences, Tehran, Iran. gholamali.shahidi@gmail.com

5. Assistant Professor of Biostatistics, Faculty of Management and Medical Informatics, Tehran University of Medical Sciences, Tehran, Iran. salehi74@yahoo.com

PD is growing. There is 3:2 ratio of males to females (2). PD results in hypokinetic dysarthria that affects all aspects of speech such as respiration, phonation, articulation and prosody (7, 8). Nearly 90% of patients have oral communication disorders (9) but "voice" is affected more and sooner than other speech subsystems (10-12). One third of Parkinson patients suffer from dysphonia and they present breathy and harsh voice as their most debilitating deficit (13). Voice disorders consist of several different aspects, therefore several measurements and scales should be used (14). Clinical evaluation of voice includes perceptual, acoustic, (video) laryngostroboscopic and aerodynamic assessments (14-16) that are very useful in clinical evaluation of neurological disorders (15, 17). Neither voice objective scales such as video/ auditory nor perceptual assessment can evaluate the amount of handicap that a patient experiences as a result of voice disorder. Patient-based measurements can add some necessary supplementary information to biological and physiological data that are associated with voice disorder (17, 18).

Voice Handicap Index (VHI) is a common questionnaire used in a wide range of voice disorders and it is the most applicable subjective self-rating questionnaire in patients who have perceived voice disability. It shows the effect of disabilities resulting from voice handicap on quality of life (QOL) (15, 16). VHI is a perceptual analysis tool of voice quality that shows us the influence of voice problems and their treatments on patients QOL (19).

Like other neurodegenerative disorders the severity of the PD progresses over the time (20, 21). There are several ways to assess motor performance and disease severity in PD. The Unified Parkinson's Disease Rating Scale (UPDRS) is the most common tool for clinical evaluation of PD (2) and measures motor and some of non-motor symptoms of PD. The 3rd part of the test (UPDRS-III) evaluates all fundamental motor characteristics of PD (22). In present research, movement disorder society (MDS-UPDRS) version of the test has been used. Hoehn and

Yahr (H&Y) is another scale for PD's severity that rates between 0-5 based on the level of clinical disabilities (23). There is no study about VHI in Iranian PD's patients; and therefore no research about any relation between PD's motor disabilities and voice disorder. Due to increase in Iranian aged population in future decades, PD prevalence will increase as well (24), and necessity of these kinds of studies are obvious. Several studies express VHI progression in PD and suggest the effective role of VHI in determination of voice disorder influence on PD's quality of life (25-27). The only research about relation between movement disabilities and VHI in PD under pharmacologic therapy is a study by Midi et al (28). It hasn't found any correlation between VHI and disease severity (UPDRS-III). Frost et al (25) did not find any relation between VHI and UPDRS in patients under surgical therapy (Deep-Brain Stimulation of the Subthalamic Nucleus /STN-DBS). The purpose of this study is to examine correlations between disease severity and handicap due to voice disorder; and whether the VHI score increases with the increase of disease severity, and also the relation between VHI domains (Physical, functional, emotional) and disease severity. Some objective and subjective studies in PD have been reported several different items by sex (29-31) and some findings have suggested that certain speech characteristics are different in male and females (32-37). Hence the role of sex and probable differences (in PD voice handicap index) based on sexuality was another purpose of this study.

### Methods

This cross-sectional, analytical and non-interventional study was carried out on 23 PD patients who were chosen from attendants of movement disorders clinic of Rasool Akram Hospital, from January until June of 2011. Tehran University of Medical Sciences ethics committee approved the study and all of patients signed the consent form. Their demographic characteristics (table 1) and drug information were recorded. All of participants used levodopa as the main drug.

Table 1. Basic characteristics of patients with Parkinson's disease.

Variables	Male(13)	Female(10)	Total(23)
Age	63.23±8.64	59.1±7.76	61.435±8.26
Duration of disease	8.538±4.858	11.2±8.189	9.696±6.49
Disease severity(H&Y)	2.08±0.277	2.30±0.483	2.17±0.388
Disease severity (UPDRS-III)	31.08±14.511	32.90±12.378	31.87±13.35

H&Y: Hoehn and Yahr Scale, UPDRS: Unified Parkinson's Disease Rating Scale

Table 2. Means, standard deviation (SD) and P-values of VHI and 3domains scores

Variables	Male(13)	Female(10)	p-value	Total(23)
VHI-total	42.85±28.032	32.20±24.621	0.345	38.22±26.565
VHI-P	13.77±8.662	10.80±7.300	0.383	12.48±8.06
VHI-F	16.69±10.443	13±10.435	0.411	15.09±10.37
VHI-E	12.38±9.870	8.40±8.316	0.306	10.65±9.247

VHI: Voice Handicap Index, VHI-P: VHI Physical, VHI-F: VHI Functional, VHI-E: VHI *Emotional*

N-Methyl-D-Aspartate (NMDA) antagonists, dopamine agonist, Benzodiazepines and Selective serotonin reuptake inhibitors (SSRIs) have been among most used medications by patients. Patients pharmacotherapy, at least in recent year was under supervision of a movement disorders specialist (Shahidi). To avoid scoring bias, another neurologist expert in UPDRS scoring, participated in this research (Karkheiran). For patient selection, U.K Parkinson's Disease Society Brain Bank's clinical criteria utilized in diagnosis of probable Parkinson's disease have been used. Exclusion criteria were: suffering from another neurological or movement disorders, ages younger than 50 years, levodopa therapy under 3 month, disease onset less than 5 years (for differential diagnosis of PD from other Parkinsonism disorders) (38) and have speech therapy.

Implementation of tests was done in speech therapy department of Tehran University of Medical Sciences. None of examiners know about test results of each other. All of participants have been examined 45-90 minutes after taking the drugs so they were in the "on" state. At first, patients were evaluated according to UPDRS-III (Karkheiran), then 5-10 minutes after finishing UPDRS test, patients answered VHI questionnaire. A Speech and language pathologist was beside patients for any guide or help. To avoid fatigue and psychiatric symptoms of PD, VHI questionnaire have been taken in "on" period.

#### *Disease severity*

The part 3 of UPDRS is used for determination of disease severity. UPDRS-III consist of 18 cardinal items and according to Likert rating scale, the total score is between 0-132. Since the first item of UPDRS-III is "speech" which is so important, its scores have been analyzed individually. At the end of UPDRS-III, H&Y score (another clinical disease severity scale) has been recorded too. The UPDRS-III accomplishment for every single patient takes approximately 15 minutes. Final scores were obtained via recording every stage of this test and matching all items with the educational film was published by movement disorder society.

#### *Voice Handicap Index*

After filling VHI questionnaire by patients, its total score and 3 related domains (Physical, Functional, and Emotional) were computed separately (Table 2).

#### *Statistical analysis*

The SPSS 18.0.0 software package was used for statistical analysis. Kolmogorov-Smirnov test used to determine variables normality. Pearson and Spearman correlation coefficient was used to examine the relation between total score of UPDRS, its 18 items, VHI total score and its 3 related domains.  $\chi^2$  (for sex equality) and independent sample t-test (for compare variables means between males and females) were used with the Confidence Interval of 95% ( $p < 0.05$ ).

Table 3. Correlation between VHI (and domains), disease severity, disease duration, speech (item of UPDRS)

parameters	Severity(UPDRS)			Severity(H&Y)			Duration of disease			Speech		
	Male	Female	total	Male	female	total	Male	Female	total	Male	Female	total
VHI-T	0.473	0.579	0.485'	0.464	0.266	0.260	0.613'	0.251	0.342	0.628'	0.554	0.612''
VHI-P	0.520	0.616	0.530''	0.465	0.152	0.234	0.512	0.244	0.300	0.448	0.455	0.469'
VHI-F	0.506	0.496	0.479'	0.464	0.344	0.294	0.616'	0.338	0.391	0.632'	0.716'	0.661''
VHI-E	0.351	0.552	0.395	0.467	0.038	0.139	0.638'	0.105	0.281	0.706''	0.451	0.624''

VHI-T: VHI Total, VHI-P: VHI physical, VHI-F: VHI Functional, VHI-E: VHI Emotional

' : Correlation is significant at the 0.05 level (2-tailed)

'' : Correlation is significant at the 0.01 level (2-tailed)

## Results

This study was done on 23 PD patients reported voice disorder due to their disease. The relationship between disease severity (according to H&Y and UPDRS-III) and VHI questionnaire (and its 3 domains) was investigated. Minimum and maximum scores of UPDRS-III and H&Y were 11-69 and 2-3. Mean VHI scores (total and all of 3 domains) of males were higher than females (Table 2), however significant difference was not observed (Table 2, p-values).

### *Relation between VHI and disease severity:*

Based on H&Y ( $r=0.260$ ), there was not any relationship between VHI score and disease severity. The same result observed in both sex (Table 3). A positive correlation was found between total VHI (VHI-T) score and disease severity, according to UPDRS-III ( $r=0.485$ ). However, no relation was observed between these two variables in males and females (Table 3). There was not any relationship between VHI domains scores (Physical, Functional, Emotional) and H&Y scale, in all of patients and by sex segregation. There were positive correlations between VHI physical and functional scores; and UPDRS-III in all participants ( $r_P=0.530$ ,  $r_F=0.479$ ) but no sex-related correlation was present.

### *Relation between VHI and motor dysfunction:*

In present study the relationship between UPDRS-III subscales (18 items represented patient motor performance) and VHI score (total and 3 domains) was investigated. The aim of this activity was to evaluate possible relations between motor disabilities, especially speech (Table 3) recorded by sex and

VHI in all patients and in both sexes separately. 9 UPDRS-III items had correlation with VHI-T scores and its 3 domains (Table 4). The VHI-T scores ( $r=0.612$ ) and domains had a positive relation with "speech" item. In males group, VHI-T scores ( $r=0.628$ ), functional and emotional domains had correlation with speech item ( $r_F=0.632$ ,  $r_E=0.706$ ) but in females just functional domain showed significant relation with speech item ( $r=0.716$ ).

### *Relation between VHI and disease duration:*

There was no correlation between VHI-T score and duration of disease in patients ( $r=0.342$ ) (Table 3) but VHI-T had a correlation with disease duration in male sub group ( $r=0.613$ ). Functional and emotional VHI domains showed relationship with duration of disease in males also.

## Discussion

PD is a movement disorder that causes Hypokinetic dysarthria and affects all of speech aspects including "voice". All of participants in present study reported voice difficulties. Although the males group was reported more voice handicap (resulted from PD) than females, but no statistical difference was found between two groups, similar to other research (39).

It is known that increases in movement disorder severity affect the speech subsystems like "voice". Current study confirms this phenomenon. The VHI-T cut off point in Iranian patients suffering from voice disorders was "14.5" (40); in this research, the mean VHI\_T was "38.22" which suggested that PD patients QOL (based on voice handicap) were out of normal range. The positive correlation between VHI\_T, physical and

Table 4. significant correlation between VHI (and domains) and motor examination factors of UPDRS-III

Variables	VHI-P	VHI-F	VHI-E	VHI-T
Speech	0.469	0.661	0.624	0.612
Facial expression	0.475	0.516	0.435	0.513
Leg agility	0.534	0.565	0.611	0.603
Arising from chair	0.464	0.292	0.273	0.357
Gait	0.784	0.693	0.739	0.753
Posture	0.528	0.409	0.475	0.493
Spontaneity of movement(body bradykinesia)	0.739	0.616	0.701	0.709
Rest tremor amplitude	0.506	0.464	0.487	0.481
Constancy of rest tremor	0.493	0.400	0.425	0.433

VHI-P: VHI physical, VHI-F: VHI Functional, VHI-E: VHI Emotional, VHI-T: VHI Total

Correlation is significant at the 0.05 level (2-tailed)

functional scores and disease severity (UPDRS-III) imply that patient's perception of handicap resulted from voice disorder gets worse with increasing of disease severity. Midi (28) did not find any relation between UPDRS and VHI-T. That is why the participants in his study were in their first 5 years of disease and therefore, their motor impairment severity was mild. But, in present study, minimum duration of disease was 5 years and severity range included mild to severe (UPDRS 11-69). Not finding a relation between VHI-T and disease severity (H&Y) may be due to lower H&Y sensitivity and accuracy rather than UPDRS.

Speech item (first UPDRS item) has strong relation with VHI scores (table4). This finding shows patient perception of voice situation is consistent with clinical scores determined by neurologist (by motor assessment). The interesting issue is the positive correlation between 9 items of UPDRS and VHI (total and subscales scores). In previous conducted studies (41), less and weaker relations between speech characteristics and UPDRS were observed. This may suggest an accurate and important patient viewpoint about voice disorder and its handicap. "Signs and symptoms" are 2 terms that are frequently used in voice assessment. "Signs" are observable and testable voice characteristics but "symptoms" are the patient reports and complaints about voice problem (23). Patient based voice evaluation, like VHI, can help us to diagnosis and treatment of voice disorder.

Even though it was expected that the in-

crease of VHI would be correlated with the disease duration, such result were not observed. There was a strong correlation between VHI-T, functional & emotional scores and duration of PD in males. A larger sample size may help to find these relations in females and all patients as a group.

### Conclusion

Iranian PD patients feel handicap due to voice disorder caused by PD and their quality of life was affected by voice impairment. Voice assessment, especially patient-based voice evaluation such as VHI, is an important offered issue used in PD beside other assessments. These kinds of studies can help us identify problems and treatment preferences.

### Acknowledgements

The authors are grateful to participants and their families for their cooperation and patience. Special thanks to Mrs. Mahmudi, secretary of movement disorder clinic, for her kindness and help.

### References

1. Khoo TK, Burn DJ. Non-motor symptoms may herald Parkinson's disease. *Practitioner*2009 Sep; 253(1721):19-24, 2.
2. Fahn S, Jankovic J. principles and practice of movement disorders. Philadelphia: Churchill Livingstone Elsevier; 2007.pp. 212-22.
3. Goberman AM. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson Disease. *Med Sci Monit*2005 Mar; 11(3):CR109-16.

4. Goberman AM, Blomgren M. Fundamental frequency change during offset and onset of voicing in individuals with Parkinson disease. *J Voice* 2008 Mar;22(2):178-91.
5. Chen JJ. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. *Am J Manag Care* 2010 Mar; 16 Suppl Implications:S87-93.
6. Harel BT, Cannizzaro MS, Cohen H, Reilly N, Snyder PJ. Acoustic characteristics of Parkinsonian speech: a potential biomarker of early disease progression and treatment. *Journal of Neurolinguistics* 2004; 17(6):439-53.
7. Skodda S, Visser W, Schlegel U. Vowel Articulation in Parkinson's Disease. *Journal of Voice*2010; 25(4):467-72.
8. Mate MA, Cobeta I, Jimenez-Jimenez FJ, Figueiras R. Digital Voice Analysis in Patients With Advanced Parkinson's Disease Undergoing Deep Brain Stimulation Therapy. *J Voice* Jun 24.
9. Zarzur AP, Duarte IS, Goncalves Gdo N, Martins MA. Laryngeal electromyography and acoustic voice analysis in Parkinson's disease: a comparative study. *Braz J Otorhinolaryngol*2010 Feb; 76(1):40-3.
10. Logemann JA, Fisher HB, Boshes B, Blonsky ER. Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. *J Speech Hear Disord*1978 Feb; 43(1):47-57.
11. Zwirner P, Barnes GJ. Vocal tract steadiness: a measure of phonatory and upper airway motor control during phonation in dysarthria. *J Speech Hear Res*1992 Aug; 35(4):761-8.
12. Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of patients with Parkinson's disease. *Behav Neurol*1998; 11(3):131-7.
13. Sewall GK, Jiang J, Ford CN. Clinical evaluation of Parkinson's- related dysphonia. *Laryngoscope*2006 Oct; 116(10):1740-4.
14. Hakkesteegt MM, Brocaar MP, Wieringa MH. The applicability of the dysphonia severity index and the voice handicap index in evaluating effects of voice therapy and phonosurgery. *J Voice* 2009 Mar; 24(2):199-205.
15. Schindler A, Ottaviani F, Mozzanica F, Bachmann C, Favero E, Schettino I, et al. Cross-cultural adaptation and validation of the Voice Handicap Index into Italian. *J Voice* 2010 Nov; 24(6):708-14.
16. Behlau M, Alves Dos Santos Lde M, Oliveira G. Cross-cultural adaptation and validation of the voice handicap index into Brazilian Portuguese. *J Voice*2011 May; 25(3):354-9.
17. Gamboa J, Jimenez-Jimenez FJ, Mate MA, Cobeta I. [Voice disorders caused by neurological diseases]. *Rev Neurol* 2001 Jul 16-31; 33(2):153-68.
18. Helidoni ME, Murry T, Moschandreas J, Lionis C, Printza A, Velegrakis GA. Cross-cultural adaptation and validation of the voice handicap index into Greek. *J Voice* 2010 Mar; 24(2):221-7.
19. Maertens K, de Jong FI. The voice handicap index as a tool for assessment of the biopsychosocial impact of voice problems. *B-ENT* 2007; 3(2):61-6.
20. Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times. *Mov Disord* 2010 Apr 30; 25(6):710-6.
21. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. *Neurology* 2005 Nov 8; 65(9):1436-41.
22. Muller T, Harati A. Diadochokinetic movements differ between patients with Parkinson's disease and controls. *J Neural Transm* 2010 Feb; 117(2):189-95.
23. Colton RH, Casper JK, Leonard R. understanding voice problems: a physiological perspective for diagnosis and treatment. 3rd ed. philadelphia: lipincott Williams and Wilkins; 2006.
24. Ghadirzadeh M, Fadaievatan R, Akbarikamrani A, Davatgaran K, Hasheminazari S, Mirtorabi D. Road Accident Mortality of the Iranian Elderly from 2006 to 2008. *Salmand (Iranian Journal of Aging)* 2012; 7(23).
25. Frost E, Tripoliti E, Hariz MI, Pring T, Limousin P. Self-perception of speech changes in patients with Parkinson's disease following deep brain stimulation of the subthalamic nucleus. *Int J Speech Lang Pathol* Oct; 12(5):399-404.
26. Bauer V, Aleric Z, Jancic E, Miholovic V. Voice quality in Parkinson's disease in the Croatian language speakers. *Coll Antropol*2011 2012; 35 Suppl 2:209-12.
27. Spielman J, Ramig LO, Mahler L, Halpern A, Gavin WJ. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease. *Am J Speech Lang Pathol*2007 May; 16(2):95-107.
28. Midi I, Dogan M, Koseoglu M, Can G, Sehitoğlu MA, Gunal DI. Voice abnormalities and their relation with motor dysfunction in Parkinson's disease. *Acta Neurol Scand*2008 Jan; 117(1):26-34.
29. Accolla E, Caputo E, Cogiamanian F, Tamma F, Mrakic-Spota S, Marceglia S, et al. Gender differences in patients with Parkinson's disease treated with subthalamic deep brain stimulation. *Mov Disord*2007 Jun 15; 22(8):1150-6.
30. Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. *Neurology* 2009 Nov 3; 73(18):1469-77.
31. Bayes-Rusinol A, Forjaz MJ, Ayala A, Crespo Mde L, Prats A, Valles E, et al. [Awareness of dysphagia in Parkinson's disease]. *Rev Neurol* 2011 Dec 1; 53(11):664-72.
32. Goberman AM, Coelho C. Acoustic analysis of parkinsonian speech I: speech characteristics and L-Dopa therapy. *NeuroRehabilitation*2002;17(3):237-46.

33. Gamboa J, Jiménez-Jiménez FJ, Nieto A, Montojo J, Ort-Pareja M, Molina JA, et al. Acoustic voice analysis in patients with Parkinson's disease treated with dopaminergic drugs. *Journal of Voice* 1997; 11(3):314-20.
34. Jimenez-Jimenez FJ, Gamboa J, Nieto A, Guerrero J, Orti-Pareja M, Molina JA, et al. Acoustic voice analysis in untreated patients with Parkinson's disease. *Parkinsonism Relat Disord* 1997 Apr; 3(2):111-6.
35. Hertrich I, Ackermann H. Gender-specific vocal dysfunctions in Parkinson's disease: electroglottographic and acoustic analyses. *Ann Otol Rhinol Laryngol* 1995 Mar; 104(3):197-202.
36. Skodda S, Visser W, Schlegel U. Gender-Related Patterns of Dysprosody in Parkinson Disease and Correlation between Speech Variables and Motor Symptoms. *J Voice* 2009 Apr 8.
37. Skodda S, Rinsche H, Schlegel U. Progression of dysprosody in Parkinson's disease over time--a longitudinal study. *Mov Disord* 2009; 24(5):716-22.
38. Lang AE, Widner H. Deep brain stimulation for Parkinson's disease: patient selection and evaluation. *Mov Disord* 2002;17 Supp 13: S94-101.
39. Krischke S, Weigelt S, Hoppe U, Kollner V, Klotz M, Eysholdt U, et al. Quality of life in dysphonic patients. *J Voice* 2005 Mar; 19(1):132-7.
40. Moradi N, Soltani M, Javadipoor S, Poorshahbaz A, Hashemi H, Soltani N. Cross-Cultural Adaptation and Validation of the Voice Handicap Index into Iranian 10th Iranian congress of Speech Therapy; Ahvaz: Ahvaz Jundishapur University of Medical sciences 2011; p14.
41. Madjdinasab F, Jalilevand N, Shahidi G, Moradi N, Karkheiran S, Salehi M. Relation between oral diadochokinesis and disease severity in Iranian patients with idiopathic Parkinson's disease *Iranian Journal of War and Public Health* 2011.